We’re ending our time at #ASHG25 with a bang! Today, we presented a poster titled “Electronic Genome Mapping of Somatic Structural Variants,” which highlighted the OhmX Platform’s unique ability to reliably detect and validate cancer genomes, complex SVs that present challenges to existing research methods. We’ve had a great time at ASHG so far, and are pleased to have shared our research pioneering the next evolution of #genomics. 👉 Read the press release and learn more about the data: https://hubs.ly/Q03P9Mbz0 #Genomics #EGM #Innovation #LifeSciences #NabsysASHG2025

New trial! Angela R. Bradbury, MD, of the Perelman School of Medicine at the University of Pennsylvania leads Alliance A232301CD testing if a digital chatbot intervention is as effective as standard remote genetic services in increasing counseling uptake among adolescent and young (AYA) adult cancer patients. To learn more, visit https://lnkd.in/gpFDfzu5.

Our new review paper is published! The paper is titled “DNA methylation and machine learning: challenges and perspectives toward enhanced clinical diagnostics.” It covers how recent progress in machine learning helps analyze DNA methylation data for better clinical diagnostics in cancer, cardiovascular, neurodevelopmental, and rare diseases. The review also outlines key methods and examples that connect research findings to medical applications. Full text available at: https://lnkd.in/duhjQX6Z I’d like to thank Dr. Amir Hossein Saeidian Dr. Erfan Aref-Eshghi, MD, PhD, DABMGG, FACMG, and my co-authors Arash B. Abadi and Amirreza Hooshmand for their valuable input and collaboration throughout this work. #DNAmethylation #MachineLearning #Bioinformatics #ClinicalDiagnostics

Illumina Ventures is thrilled to share insights from Tom Willis, PhD, who took the helm as CEO of Arima Genomics in June 2025 after two decades of shaping the #genomics industry. In our latest CEO Spotlight, Tom unpacks Arima’s fascinating journey from academic spin-out to clinical disruptor. Discover how Arima’s technology goes beyond traditional sequencing, preserving the original 3D structure of DNA to unlock hidden cancer signals. 👉 Check out the full conversation in our quick 3-minute read for more insights. https://lnkd.in/eEmEku73 #CancerResearch #PrecisionMedicine #HealthcareInnovation #LifeSciences #Innovation #Leadership

Hackensack Meridian Health has entered a #partnership with SpotitEarly to study the early detection of #BreastCancer with cancer sniffing #dogs combined with #AI technology. Hear more from Elias Obeid, MD, MPH, medical director of the Hackensack Meridian Health Hennessy Institute for Cancer Prevention and Applied Molecular Medicine here : https://lnkd.in/gF_dFEVX

Cancer is one of the world's greatest health challenges, and we're determined to ensure that beating it means beating it for everyone.  To achieve this, we will support high-quality research into understanding and addressing the role of biology and its interaction with other contributing factors in shaping cancer inequalities. We’ll also ensure that the research we fund meaningfully includes underrepresented communities, so that implementing these innovations doesn’t deepen existing inequalities. By funding and supporting a diverse and inclusive community of excellent researchers, we’ll drive impactful research that benefits all.  We’re pleased to share our refreshed strategic approach to EDI in research with you. Our new approach is data-driven and focuses on areas where we can make the greatest difference in the next five years. Thank you to all the patient representatives, researchers and partners who have helped shape this work. We won’t be able to meet our ambitions alone and look forward to working with you to achieve them. 🔗 Read more about our strategic approach to EDI in research https://cruk.ink/46xQtJ1

Absolutely thrilled to see this renewed commitment to equity, diversity, and inclusion in cancer research. As trustees and patient advocates for Lynch Syndrome UK, we strongly support this strategic approach—especially its emphasis on biological factors and inclusive research design. Lynch syndrome, the most common hereditary cause of colorectal and endometrial cancers, exemplifies why this work matters. Despite its prevalence, awareness and access to genetic testing remain uneven, particularly among underrepresented communities. Research shows that disparities in diagnosis, surveillance, and treatment outcomes persist due to systemic barriers, limited clinician awareness, and gaps in culturally competent care. By investing in research that explores how inherited cancer syndromes like Lynch interact with social determinants of health, we can better understand—and begin to dismantle—these inequalities. Equally vital is ensuring that genomic studies and clinical trials include diverse populations, so that innovations in prevention and treatment are truly equitable. Thank you for recognising the value of patient voices in shaping this strategy. We look forward to collaborating to ensure that hereditary cancer research reflects the lived experiences of all communities—and delivers better outcomes for everyone.

As a trustee for Lynch Syndrome UK and someone deeply committed to inclusive, patient-led research, I wholeheartedly welcome this refreshed strategic approach to EDI. It speaks to the very heart of what we strive for: ensuring that advances in cancer care are not just innovative, but equitable. Lynch syndrome is a prime example of where inequalities persist. Despite being the most common inherited cause of bowel and endometrial cancers, many people remain undiagnosed—especially in communities that face barriers to genetic testing, culturally competent care, or even basic awareness. I’ve seen firsthand how these gaps can delay diagnosis, limit access to surveillance, and impact outcomes. That’s why this strategy matters. By funding research that explores the biological underpinnings of cancer alongside the social and systemic factors that shape inequality, we can begin to close those gaps. And by ensuring underrepresented communities are meaningfully included—not just as participants, but as co-creators of research—we can build trust and relevance into every stage of the process. I’m proud to be part of a community that centres lived experience and values collaboration. Thank you for recognising the role of patient representatives in shaping this work. Together, we can ensure that beating cancer truly means beating it for everyone.

🆕 Beating cancer means beating it for everyone!👊 Thrilled to see the launch of Cancer Research UK’s new EDI in Research Strategic Approach. This five-year plan is a bold step toward ensuring our discoveries reflect the diversity of people affected by cancer — by investing in inclusive research design, supporting diverse talent, and tackling inequalities head-on. 🔗 Read more about CRUK’s new strategic approach to EDI in research https://cruk.ink/46xQtJ1

“Genetic testing is particularly important for Black women when it comes to ovarian cancer for a number of reasons,” said Kevin Holcomb, MD, of Long Island Jewish Medical Center & North Shore University Hospital: bit.ly/3Kt97cx. He explained how genetic testing can serve as a potentially life-saving tool in this first episode of a new video series from BlackDoctor.org & OCRA.